Literature DB >> 21425978

Direct-to-consumer advertising of prescription medicines: a counter argument.

Barbara Mintzes1, Dee Mangin.   

Abstract

Direct-to-consumer advertising of prescription-only medicines is currently only permitted in the USA and New Zealand. Barbara Mintzes and Dee Mangin provide their case against direct-to-consumer advertising of prescription medicines, arguing that its wider introduction would lead to a 'Pharma-knows-best' culture.

Mesh：

Substances：

Year:  2009        PMID： 21425978     DOI： 10.4155/fmc.09.136

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


  3 in total

1.  Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?

Authors:  C Lee Ventola
Journal:  P T       Date:  2011-10

2.  Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada.

Authors:  Lingyun Lu; Harlan M Krumholz; Jack V Tu; Joseph S Ross; Dennis T Ko; Cynthia A Jackevicius
Journal:  Am Heart J       Date:  2014-02-26       Impact factor: 4.749

3.  'At-risk' individuals' responses to direct to consumer advertising of prescription drugs: a nationally representative cross-sectional study.

Authors:  Neda Khalil Zadeh; Kirsten Robertson; James A Green
Journal:  BMJ Open       Date:  2017-12-06       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.